Table 3.
Cardiac Functional Parameters Determined by Magnetic Resonance Imaging
| Sham | Vehicle | Sacubitril/Valsartan | Valsartan | NC | mir‐181a antagomir | miR‐181a mimic | miR‐181a mimic +Sacubitril/Valsartan | |
|---|---|---|---|---|---|---|---|---|
| LVEF (%) w2 | 58.76±1.2 | 43.68±3.2 | 44.80±6.24 | 43.24±4.5 | 41.28±5.7 | 44.51±2.9 | 42.24±3.7 | 40.89±3.6 |
| LVEF (%) w8 | 61.32±2.9 | 36.79±2.1 | 41.42±3.4a | 40.68±4.8a | 40.22±6.7 | 44.75±3.7b | 40.81±3.74 | 39.13±4.5 |
| LVEDV (μL) w2 | 333.53±54.1 | 508.7±99.3 | 523.49±138.7 | 519.7±53.13 | 574.07±126.2 | 482.74±58.0 | 499.19±99.13 | 525.11±112.3 |
| LVEDV (μL) w8 | 411.69±23.7 | 578.82±99.9 | 584.74±158.0 | 522.69±68.4 | 712.28±154.5 | 533.16±47.0 | 614.85±102.6 | 654.16±126.20 |
| LVESV (μL) w2 | 137.20±19.2 | 285±50.8 | 295.92±105.62 | 276.05±64.95 | 342.93±104.9 | 268.01±37.2b | 288.74±63.4 | 312.50±79.0 |
| LVESV (μL) w8 | 159.45±17.6 | 365.64±63.1 | 300.45±115.2 | 269.03±64.9 | 428.89±138.4 | 295.12±138.4b | 295.12±102.5 | 401.26±98.3 |
| LVM (mg) w2 | 332.38±11.7 | 426.25±34.7 | 391.43±62.1 | 384.9±45.7 | 448.28±67.11 | 392.51±27.7b | 392.51±55.5 | 383.94±65.9 |
| LVM (mg) w8 | 365.52±18.4 | 426.25±34.7 | 391.4±62.1 | 369.7±45.7 | 508.66±47.2 | 413.31±5.7b | 504.36±85.9 | 532.16±115.1 |
LVEDV indicates left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; LVM, left ventricular mass; NC, negative control.
a
P<0.05 relative to sham group.
b
P<0.05 relative to NC.